Home › Glioblastoma › NCT05139277
Evaluation of the CONVIVO System
Clinical Investigation to Evaluate the CONVIVO System for Discrimination of Normal From Abnormal Tissue During Brain Tumor Resection
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients (age\>18) * Adults presenting with suspected intracranial gliomas (including glioblastoma), cerebral metastasis, meningiomas, acoustic neuromas, and pituitary adenomas, who are surgical candidates * Adults able to provide informed consent. Exclusion Criteria: * Pregnancy * Children (age \<18 years) * Fluorescein sodium (FNa) allergy
About the study
The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and conventional histologic interpretation.
What is being tested
- CONVIVO system (diagnostic test)
- Conventional histologic evaluation (other)
Sponsor: Dartmouth-Hitchcock Medical Center · Participants: 30 · Started: Jun 28, 2022
Contact the study team
- Linton T Evans, MD · Phone: 603-650-5026
Official record on ClinicalTrials.gov — NCT05139277
Locations in the U.S.
| New Hampshire | Dartmouth-Hitchcock Medical Center, Lebanon |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.